Hims & Hers Hit With Short Seller Wrecking Ball: Spruce Point Cites 'No Cost Advantage', Legal Concerns
Portfolio Pulse from Chris Katje
Healthcare company Hims & Hers Health (NYSE:HIMS) is under scrutiny by short seller Spruce Point Capital, which has raised several red flags about the company's legal structure and business practices. Spruce Point questions the operations of Hims & Hers, suggesting potential legal and business repercussions. Despite the criticism, shares of Hims & Hers were up 5.31% to $9.12 on Thursday. The company's shares have risen 69% in the last year and 45% year-to-date in 2023.
July 13, 2023 | 8:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hims & Hers Health is under scrutiny by short seller Spruce Point Capital, which has raised concerns about the company's legal structure and business practices. Despite this, HIMS shares were up 5.31% on Thursday.
Despite the negative report from Spruce Point Capital, Hims & Hers Health's stock price increased, indicating that investors may not be overly concerned about the short seller's claims. However, the legal and business concerns raised could potentially impact the company's stock price in the future.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100